OBJECTIVES: To investigate whether plasma cell-free DNA (cfDNA) or its integrity could differentiate prostate cancer from benign prostate hyperplasia (BPH) in patients with serum prostate-specific antigen (PSA) ≥ 4 ng/ml. METHODS: Ninety-six patients with prostate cancer and 112 patients with BPH were enrolled. cfDNA levels in plasma before prostate biopsy were quantified by real-time PCR amplification of ALU gene (product size of 115 bp), and quantitative ratio of ALU (247 bp) to ALU (115 bp) reflected the integrity of cfDNA. RESULTS: In patients with serum PSA ≥ 4 ng/ml, there were significant differences in plasma cfDNA or its integrity between the patients with prostate cancer (19.74 ± 4.43, 0.34 ± 0.05) and patients with BPH (7.36 ± 1.58, 0.19 ± 0.03; P < 0.001, P < 0.001). Prostate cancer could be differentiated with a sensitivity of 73.2 % and a specificity of 72.7 % by cfDNA (AUC = 0.864). The integrity of cfDNA had a sensitivity of 81.7 % and a specificity of 78.8 % for the distinguishing prostate cancer from BPH (AUC = 0.910). CONCLUSIONS: cfDNA and its integrity could be applied to differentiate prostate cancer from BPH in patients with serum PSA ≥ 4 ng/ml.
OBJECTIVES: To investigate whether plasma cell-free DNA (cfDNA) or its integrity could differentiate prostate cancer from benign prostate hyperplasia (BPH) in patients with serum prostate-specific antigen (PSA) ≥ 4 ng/ml. METHODS: Ninety-six patients with prostate cancer and 112 patients with BPH were enrolled. cfDNA levels in plasma before prostate biopsy were quantified by real-time PCR amplification of ALU gene (product size of 115 bp), and quantitative ratio of ALU (247 bp) to ALU (115 bp) reflected the integrity of cfDNA. RESULTS: In patients with serum PSA ≥ 4 ng/ml, there were significant differences in plasma cfDNA or its integrity between the patients with prostate cancer (19.74 ± 4.43, 0.34 ± 0.05) and patients with BPH (7.36 ± 1.58, 0.19 ± 0.03; P < 0.001, P < 0.001). Prostate cancer could be differentiated with a sensitivity of 73.2 % and a specificity of 72.7 % by cfDNA (AUC = 0.864). The integrity of cfDNA had a sensitivity of 81.7 % and a specificity of 78.8 % for the distinguishing prostate cancer from BPH (AUC = 0.910). CONCLUSIONS: cfDNA and its integrity could be applied to differentiate prostate cancer from BPH in patients with serum PSA ≥ 4 ng/ml.
Authors: Annalisa Altimari; Antonia D'Errico Grigioni; Elisa Benedettini; Elena Gabusi; Riccardo Schiavina; Antonio Martinelli; Antonio Maria Morselli-Labate; Giuseppe Martorana; Walter Franco Grigioni; Michelangelo Fiorentino Journal: Am J Clin Pathol Date: 2008-05 Impact factor: 2.493
Authors: F Strittmatter; P Stieber; D Nagel; C Füllhase; S Walther; C G Stief; R Waidelich Journal: Eur J Med Res Date: 2011-10-10 Impact factor: 2.175
Authors: Brant G Wang; Han-Yao Huang; Yu-Chi Chen; Robert E Bristow; Keyanunoosh Kassauei; Chih-Chien Cheng; Richard Roden; Lori J Sokoll; Daniel W Chan; Ie-Ming Shih Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166